Literature DB >> 12390952

Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma.

Kevin D O'Brien1, David M Shavelle, Michael T Caulfield, Thomas O McDonald, Katherine Olin-Lewis, Catherine M Otto, Jeffrey L Probstfield.   

Abstract

BACKGROUND: Recent studies have demonstrated that lesions of aortic sclerosis and stenosis share several similarities with lesions of atherosclerosis. In atherosclerosis, angiotensin-converting enzyme (ACE) is expressed by a subset of macrophages. This study was undertaken to determine whether ACE might be present in aortic sclerosis or stenosis lesions. METHODS AND
RESULTS: Immunohistochemistry was performed on 26 paraffin-embedded human aortic valves. Monospecific antibodies were used to identify ACE, macrophages, angiotensin II type 1 receptor (AT-1 receptor), angiotensin II, and apolipoprotein B. Human low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were isolated from plasma of normal volunteers by sequential density-gradient ultracentrifugation. ACE was not present in normal valves but was present in all valves with aortic sclerosis or stenosis lesions. ACE was detected on a subset of lesion macrophages but was present primarily in an extracellular distribution, where it colocalized with apolipoprotein B. ACE was detected by Western blotting on plasma LDL but not on HDL isolated from normal volunteers. Angiotensin II, the enzymatic product of ACE, was colocalized with ACE in valve lesions. ACE also was colocalized with apolipoprotein B in an adjacent coronary atherosclerotic plaque.
CONCLUSIONS: ACE is present in aortic sclerosis and stenosis lesions, where it may participate in lesion development, as is evidenced by the presence of its enzymatic product, angiotensin II. The observation of an association of ACE with LDL in both lesions and plasma suggests that LDL may deliver ACE to lesions and has implications for the role of ACE-containing LDL in other diseases, such as atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12390952     DOI: 10.1161/01.cir.0000035655.45453.d2

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  74 in total

1.  Targeted therapy to prevent progression of calcific aortic stenosis.

Authors:  Nalini M Rajamannan; Catherine M Otto
Journal:  Circulation       Date:  2004-09-07       Impact factor: 29.690

2.  Risk factors for progression of calcific aortic stenosis and potential therapeutic targets.

Authors:  Ashvin R Kamath; Ramdas G Pai
Journal:  Int J Angiol       Date:  2008

3.  Administration of angiotensin-converting enzyme inhibitors is associated with slow progression of mild aortic stenosis in Japanese patients.

Authors:  Kana Wakabayashi; Takeshi Tsujino; Yoshiro Naito; Akira Ezumi; Masaaki Lee-Kawabata; Shinji Nakao; Akiko Goda; Yasushi Sakata; Kazuhiro Yamamoto; Takashi Daimon; Tohru Masuyama
Journal:  Heart Vessels       Date:  2010-11-10       Impact factor: 2.037

4.  Aortic stenosis: An update.

Authors:  Sangeetha Nathaniel; Shreyas Saligram; Antony Leslie Innasimuthu
Journal:  World J Cardiol       Date:  2010-06-26

Review 5.  Calcific aortic valve disease: not simply a degenerative process: A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease-2011 update.

Authors:  Nalini M Rajamannan; Frank J Evans; Elena Aikawa; K Jane Grande-Allen; Linda L Demer; Donald D Heistad; Craig A Simmons; Kristyn S Masters; Patrick Mathieu; Kevin D O'Brien; Frederick J Schoen; Dwight A Towler; Ajit P Yoganathan; Catherine M Otto
Journal:  Circulation       Date:  2011-10-18       Impact factor: 29.690

Review 6.  Aortic stenosis: medical and surgical management.

Authors:  Helmut Baumgartner
Journal:  Heart       Date:  2005-11       Impact factor: 5.994

7.  Is it time for medical therapy for aortic valve disease?

Authors:  Nalini M Rajamannan
Journal:  Expert Rev Cardiovasc Ther       Date:  2004-11

Review 8.  The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology.

Authors:  Amber C Liu; Vineet R Joag; Avrum I Gotlieb
Journal:  Am J Pathol       Date:  2007-09-06       Impact factor: 4.307

9.  Serotonin and catecholamines in the development and progression of heart valve diseases.

Authors:  Elliott Goldberg; Juan B Grau; Jacqueline H Fortier; Elisa Salvati; Robert J Levy; Giovanni Ferrari
Journal:  Cardiovasc Res       Date:  2017-07-01       Impact factor: 10.787

10.  Effects of the coronary artery disease associated LPA and 9p21 loci on risk of aortic valve stenosis.

Authors:  Teresa Trenkwalder; Christopher P Nelson; Muntaser D Musameh; Ify R Mordi; Thorsten Kessler; Costanza Pellegrini; Radoslaw Debiec; Tobias Rheude; Viktor Lazovic; Lingyao Zeng; Andreas Martinsson; J Gustav Smith; Jesper R Gådin; Anders Franco-Cereceda; Per Eriksson; Jonas B Nielsen; Sarah E Graham; Cristen J Willer; Kristian Hveem; Adnan Kastrati; Peter S Braund; Colin N A Palmer; Amparo Aracil; Oliver Husser; Wolfgang Koenig; Heribert Schunkert; Chim C Lang; Christian Hengstenberg; Nilesh J Samani
Journal:  Int J Cardiol       Date:  2018-11-17       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.